Tag: Lynk Pharmaceuticals Co.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsLynk Pharmaceuticals Co.

AIFA 就涉及 HyalRoute Communication Group Limited 的股份收購交易正式作出澄清及反駁

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

Tag: Lynk Pharmaceuticals Co.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us